GeneDx Holdings Corp. (WGS) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US81663L2007
GeneDx Holdings Corp. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 427.54 m USD |
| Gross profit | 298.17 m USD |
| Operating income | -13.08 m USD |
| EBIT | -21.14 m USD |
| Net income | -21.02 m USD |
| Diluted EPS – continuing operations | -0.73 USD |
Full history since 2018, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About GeneDx Holdings Corp.
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.
More stocks
- Indah Kiat Pulp & Paper Tbk (INKP.JK)
- Ashmore Group PLC (ASHM.L)
- Shenzhen Everbest Machinery Indus (002980.SZ)
- Cairn Homes PLC (CRN.L)
- Vivendi SE (VIV.PA)
- Beijing Hualian Hypermarket Co Ltd (600361.SS)
- Freehold Royalties Ltd (FRU.TO)
- ISC Co. Ltd (095340.KQ)
- UBE Corp (4208.T)
- Kier Group PLC (KIE.L)
- Uxi Unicomp Technology Co. Ltd. A (688531.SS)
- Vale Indonesia Tbk (INCO.JK)
Not investment advice. All data without warranty, price as of 28.10.2026. Details in the risk notice.